Author: He, Biao; Fu, Yuhong; Xia, Shuai; Yu, Fei; Wang, Qian; Lu, Lu; Jiang, Shibo
Title: Intranasal application of polyethyleneimine suppresses influenza virus infection in mice Document date: 2016_4_27
ID: 0rg6n7fr_6
Snippet: In summary, we demonstrated that PEI, a mucosal stimulant for topical intranasal administration, is highly effective in preventing influenza virus infection. Compared to the bacteria-produced toxin CTB, the chemically synthesized polymer PEI is safer for mucosal application in humans. PEI has been tested in several clinical trials for gene delivery in vivo, demonstrating a good safety profile. 9 Moreover, its low cost of production and abundance .....
Document: In summary, we demonstrated that PEI, a mucosal stimulant for topical intranasal administration, is highly effective in preventing influenza virus infection. Compared to the bacteria-produced toxin CTB, the chemically synthesized polymer PEI is safer for mucosal application in humans. PEI has been tested in several clinical trials for gene delivery in vivo, demonstrating a good safety profile. 9 Moreover, its low cost of production and abundance makes PEI more suitable for urgent and widespread use during a time of influenza epidemic or pandemic.
Search related documents:
Co phrase search for related documents- bacteria produce and clinical trial: 1
- bacteria produce and influenza virus: 1, 2
- clinical trial and good safety profile: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- clinical trial and influenza epidemic: 1, 2
- clinical trial and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44
- clinical trial and influenza virus infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- clinical trial and intranasal administration: 1, 2, 3, 4, 5, 6, 7
- clinical trial and low cost: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
- clinical trial and mucosal application: 1
- clinical trial and safety profile: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- gene delivery and influenza virus: 1, 2, 3, 4, 5, 6, 7
- gene delivery and influenza virus infection: 1, 2
- gene delivery and intranasal administration: 1, 2, 3, 4, 5
- gene delivery and low cost: 1
- gene delivery and safety profile: 1, 2, 3, 4
- gene delivery and vivo gene delivery: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- good safety profile and influenza virus: 1
- good safety profile and intranasal administration: 1, 2
- good safety profile and low cost: 1, 2
Co phrase search for related documents, hyperlinks ordered by date